

Richard J Mead

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3931120/publications.pdf>

Version: 2024-02-01

28
papers

2,218
citations

516710

16
h-index

501196

28
g-index

31
all docs

31
docs citations

31
times ranked

3381
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of the Precision in Measuring Glutathione at 3% With a MEGA-PRESS Sequence in Primary Motor Cortex and Occipital Cortex. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 55, 435-442.	3.4	2
2	Caudal-Rostral Progression of Alpha Motoneuron Degeneration in the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis. <i>Antioxidants</i> , 2022, 11, 983.	5.1	1
3	Fiber optic Raman spectroscopy for the evaluation of disease state in Duchenne muscular dystrophy: An assessment using the <i>mdx</i> model and human muscle. <i>Muscle and Nerve</i> , 2022, 66, 362-369.	2.2	4
4	<i>In Vivo</i> Fiber Optic Raman Spectroscopy of Muscle in Preclinical Models of Amyotrophic Lateral Sclerosis and Duchenne Muscular Dystrophy. <i>ACS Chemical Neuroscience</i> , 2021, 12, 1768-1776.	3.5	12
5	Adipose-derived stem cells protect motor neurons and reduce glial activation in both <i>in vitro</i> and <i>in vivo</i> models of ALS. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 21, 413-433.	4.1	11
6	Proteomic Approaches to Study Cysteine Oxidation: Applications in Neurodegenerative Diseases. <i>Frontiers in Molecular Neuroscience</i> , 2021, 14, 678837.	2.9	10
7	The GLP-1 receptor agonist, liraglutide, fails to slow disease progression in SOD1G93A and TDP-43Q331K transgenic mouse models of ALS. <i>Scientific Reports</i> , 2021, 11, 17027.	3.3	5
8	Extensive phenotypic characterisation of a human TDP-43Q331K transgenic mouse model of amyotrophic lateral sclerosis (ALS). <i>Scientific Reports</i> , 2021, 11, 16659.	3.3	12
9	NRF2 as a therapeutic opportunity to impact in the molecular roadmap of ALS. <i>Free Radical Biology and Medicine</i> , 2021, 173, 125-141.	2.9	21
10	Confocal Endomicroscopy of Neuromuscular Junctions Stained with Physiologically Inert Protein Fragments of Tetanus Toxin. <i>Biomolecules</i> , 2021, 11, 1499.	4.0	0
11	Applications of machine learning to diagnosis and treatment of neurodegenerative diseases. <i>Nature Reviews Neurology</i> , 2020, 16, 440-456.	10.1	257
12	Female sex mitigates motor and behavioural phenotypes in TDP-43Q331K knock-in mice. <i>Scientific Reports</i> , 2020, 10, 19220.	3.3	9
13	Sarm1 deletion suppresses TDP-43-linked motor neuron degeneration and cortical spine loss. <i>Acta Neuropathologica Communications</i> , 2019, 7, 166.	5.2	60
14	TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. <i>Nature Neuroscience</i> , 2018, 21, 552-563.	14.8	181
15	Advances, challenges and future directions for stem cell therapy in amyotrophic lateral sclerosis. <i>Molecular Neurodegeneration</i> , 2017, 12, 85.	10.8	51
16	Early Detection of Motor Dysfunction in the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis (ALS) Using Home Cage Running Wheels. <i>PLoS ONE</i> , 2014, 9, e107918.	2.5	16
17	S[+] Apomorphine is a CNS penetrating activator of the Nrf2-ARE pathway with activity in mouse and patient fibroblast models of amyotrophic lateral sclerosis. <i>Free Radical Biology and Medicine</i> , 2013, 61, 438-452.	2.9	54
18	Optimised and Rapid Pre-clinical Screening in the SOD1G93A Transgenic Mouse Model of Amyotrophic Lateral Sclerosis (ALS). <i>PLoS ONE</i> , 2011, 6, e23244.	2.5	80

#	ARTICLE	IF	CITATIONS
19	Systemic Delivery of scAAV9 Expressing SMN Prolongs Survival in a Model of Spinal Muscular Atrophy. <i>Science Translational Medicine</i> , 2010, 2, 35ra42.	12.4	246
20	Guidelines for preclinical animal research in ALS/MND: A consensus meeting. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2010, 11, 38-45.	2.1	293
21	An in vitro screening cascade to identify neuroprotective antioxidants in ALS. <i>Free Radical Biology and Medicine</i> , 2009, 46, 1127-1138.	2.9	86
22	Oxidative stress in ALS: A mechanism of neurodegeneration and a therapeutic target. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2006, 1762, 1051-1067.	3.8	382
23	Impairment of mitochondrial anti-oxidant defence in SOD1-related motor neuron injury and amelioration by ebselen. <i>Brain</i> , 2006, 129, 1693-1709.	7.6	57
24	Deficiency of the complement regulator CD59a enhances disease severity, demyelination and axonal injury in murine acute experimental allergic encephalomyelitis. <i>Laboratory Investigation</i> , 2004, 84, 21-28.	3.7	82
25	The Membrane Attack Complex of Complement Causes Severe Demyelination Associated with Acute Axonal Injury. <i>Journal of Immunology</i> , 2002, 168, 458-465.	0.8	183
26	Rat T cells express neither CD55 nor CD59 and are dependent on Crry for protection from homologous complement. <i>European Journal of Immunology</i> , 2002, 32, 502-509.	2.9	4
27	Molecular cloning, expression and characterization of the rat analogue of human membrane cofactor protein (MCP/CD46). <i>Immunology</i> , 1999, 98, 137-143.	4.4	45
28	Mannose-binding lectin alleles in a prospectively recruited UK population. <i>Lancet, The</i> , 1997, 349, 1669-1670.	13.7	47